• Dice Therapeutics

  Participated · Series C · Aug 2021

  DiCE Molecules uses its DELSCAPE DNA-encoded library platform to discover selective oral small molecules with the potential to modulate protein-protein interactions as effectively as systemic biologics. The company is initially focused on developing oral therapeutics against well-validated targets in immunology with the goal of achieving potency comparable to systemic biologic counterparts. Its lead candidate, S011806, is an oral antagonist of interleukin-17 (IL-17). DiCE is also advancing preclinical programs targeting α4ß7 integrin (for inflammatory bowel disease) and αVß1/αVß6 integrins (for idiopathic pulmonary fibrosis). The company announced a $60 million Series C-1 financing and has raised approximately $200 million to date. Proceeds are expected to support advancing the IL-17 franchise into clinical development, progression of the integrin programs, pipeline expansion and general corporate purposes. DiCE Molecules leverages a proprietary DNA-encoded library (DEL) technology combined with structural insights to generate small-molecule antagonists against protein–protein-interface (PPI) targets, with a focus on immunology. Its DEL strategy uses well-curated, target-customized libraries that enable medicinal chemistry at scale—producing more than 100,000 unique data points per target. The company has applied this approach to successfully inhibit four PPI targets, three of which are in immunology and owned outright by DiCE, while a fourth in immuno-oncology is part of a partnership with Sanofi. DiCE emphasizes progressing well-validated targets, often those validated by precursor antibodies, to lower target risk. The company recently completed an $80 million Series C financing to advance programs, and intends to use proceeds to move its lead oral IL-17 antagonist into clinical trials while advancing other preclinical PPI assets, including a pair of integrin inhibitors, and expanding its pipeline. DiCE is headquartered in South San Francisco.

• Galecto

  Participated · Equity · Sep 2020

  Galecto is a clinical-stage biopharma focused on creating first-in-class treatments for cancer and liver diseases. Through its acquisition of Damora Therapeutics, Galecto has added a portfolio of antibody therapies that target mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is a potentially best-in-class anti-mutCALR monoclonal antibody engineered for subcutaneous dosing and is expected to file an IND in mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. Two additional antibodies, DMR-002 and DMR-003, are slated to enter Phase 1 studies thereafter. Galecto’s legacy pipeline also includes GB3226, a dual ENL-YEATS and FLT3 inhibitor being advanced toward an IND submission in Q1 2026 for acute myeloid leukemia. Following the $284.9 million private placement completed alongside the Damora acquisition, management projects a cash runway into 2029, sufficient to reach multiple clinical readouts. After conversion of the new preferred shares, Galecto will have 61,998,882 common shares outstanding.

No current team members are available.